Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 19 |
| List of Tables | 17 | 3 |
| List of Figures | 20 | 1 |
| Introduction | 21 | 1 |
| Global Markets Direct Report Coverage | 21 | 1 |
| Hypersensitivity Overview | 22 | 1 |
| Therapeutics Development | 23 | 2 |
| Pipeline Products for Hypersensitivity Overview | 23 | 1 |
| Pipeline Products for Hypersensitivity Comparative Analysis | 24 | 1 |
| Hypersensitivity Therapeutics under Development by Companies | 25 | 6 |
| Hypersensitivity Therapeutics under Investigation by Universities/Institutes | 31 | 1 |
| Hypersensitivity Pipeline Products Glance | 32 | 4 |
| Late Stage Products | 32 | 1 |
| Clinical Stage Products | 33 | 1 |
| Early Stage Products | 34 | 1 |
| Unknown Stage Products | 35 | 1 |
| Hypersensitivity Products under Development by Companies | 36 | 9 |
| Hypersensitivity Products under Investigation by Universities/Institutes | 45 | 1 |
| Hypersensitivity Companies Involved in Therapeutics Development | 46 | 57 |
| Adamis Pharmaceuticals Corporation | 46 | 1 |
| Adverum Biotechnologies, Inc. | 47 | 1 |
| Aimmune Therapeutics, Inc. | 48 | 1 |
| Alfacyte Ltd | 49 | 1 |
| ALK-Abello A/S | 50 | 1 |
| Allakos Inc. | 51 | 1 |
| Allergopharma GmbH &Co. KG | 52 | 1 |
| Allergy Therapeutics Plc | 53 | 1 |
| Amgen Inc. | 54 | 1 |
| Anacor Pharmaceuticals, Inc. | 55 | 1 |
| AnaptysBio, Inc. | 56 | 1 |
| Anergis SA | 57 | 1 |
| Antigen Express, Inc. | 58 | 1 |
| Aravax Pty Ltd | 59 | 1 |
| Array BioPharma Inc. | 60 | 1 |
| ASIT biotech s.a. | 61 | 1 |
| AskAt Inc. | 62 | 1 |
| Astellas Pharma Inc. | 63 | 1 |
| BioLingus AG | 64 | 1 |
| Biomay AG | 65 | 1 |
| Biotec Pharmacon ASA | 66 | 1 |
| Boehringer Ingelheim GmbH | 67 | 1 |
| Circassia Pharmaceuticals Plc | 68 | 1 |
| DBV Technologies S.A. | 69 | 1 |
| DNJ Pharma, Inc. | 70 | 1 |
| EA Pharma Co Ltd | 71 | 1 |
| Enzene Biosciences Ltd. | 72 | 1 |
| EpiVax, Inc. | 73 | 1 |
| Fountain Biopharma Inc. | 74 | 1 |
| HAL Allergy BV | 75 | 1 |
| iCeutica, Inc. | 76 | 1 |
| ImmunoFrontier, Inc. | 77 | 1 |
| Immunomic Therapeutics, Inc. | 78 | 1 |
| Immupharma Plc | 79 | 1 |
| InMed Pharmaceuticals Inc. | 80 | 1 |
| Interprotein Corporation | 81 | 1 |
| Japan Tobacco Inc. | 82 | 1 |
| JW Pharmaceutical Corporation | 83 | 1 |
| Laboratorios LETI S.L. | 84 | 1 |
| Monosol Rx, LLC | 85 | 1 |
| NAL Pharmaceuticals Ltd. | 86 | 1 |
| Neovacs SA | 87 | 1 |
| Novartis AG | 88 | 1 |
| Ono Pharmaceutical Co., Ltd. | 89 | 1 |
| Regeneron Pharmaceuticals Inc | 90 | 1 |
| REGiMMUNE Corporation | 91 | 1 |
| Roxall Medizin GmbH | 92 | 1 |
| Sanofi | 93 | 1 |
| Sealife PHARMA GMBH | 94 | 1 |
| Stallergenes Greer plc | 95 | 1 |
| Stallergenes SAS | 96 | 1 |
| Swecure AB | 97 | 1 |
| Therabron Therapeutics, Inc. | 98 | 1 |
| Thesan Pharmaceuticals, Inc. | 99 | 1 |
| Toleranzia AB | 100 | 1 |
| United Biomedical, Inc. | 101 | 1 |
| United BioPharma, Inc. | 102 | 1 |
| Hypersensitivity Therapeutics Assessment | 103 | 12 |
| Assessment by Monotherapy Products | 103 | 1 |
| Assessment by Combination Products | 104 | 1 |
| Assessment by Target | 105 | 3 |
| Assessment by Mechanism of Action | 108 | 3 |
| Assessment by Route of Administration | 111 | 2 |
| Assessment by Molecule Type | 113 | 2 |
| Drug Profiles | 115 | 172 |
| AAT-008 Drug Profile | 115 | 1 |
| Acarovac Quattro Drug Profile | 116 | 1 |
| AK-001 Drug Profile | 117 | 1 |
| aldesleukin Drug Profile | 118 | 1 |
| AllerDM Drug Profile | 119 | 1 |
| Allergen for Allergy Drug Profile | 120 | 1 |
| Allergen for Artemisia Vulgaris Pollen Induced Allergy Drug Profile | 121 | 1 |
| Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 122 | 1 |
| Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis Drug Profile | 123 | 1 |
| Allergen for Cat Allergy Drug Profile | 124 | 1 |
| Allergen for Cat Allergy Drug Profile | 125 | 1 |
| Allergen for Cockroach Allergy Drug Profile | 126 | 1 |
| Allergen for Egg Allergy Drug Profile | 127 | 1 |
| Allergen for Fish Allergy Drug Profile | 128 | 1 |
| Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 129 | 1 |
| Allergen for Insect, Peanut, Poison Ivy and Shellfish Allergy Drug Profile | 130 | 1 |
| Allergen for Milk Allergy Drug Profile | 131 | 3 |
| Allergen for Olive Pollen Induced Allergy Drug Profile | 134 | 1 |
| Allergen for Peanut Allergy Drug Profile | 135 | 1 |
| Allergen for Peanut Allergy Drug Profile | 136 | 1 |
| Allergen for Peanut Allergy Drug Profile | 137 | 1 |
| Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 138 | 1 |
| Allergen for Ragweed Pollen Allergy Drug Profile | 139 | 1 |
| Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis Drug Profile | 140 | 1 |
| Allergen Vaccine Program Drug Profile | 141 | 1 |
| Allergy vaccine Drug Profile | 142 | 1 |
| AllerR Drug Profile | 143 | 2 |
| AllerT Drug Profile | 145 | 3 |
| AN-3485 Drug Profile | 148 | 1 |
| ANB-020 Drug Profile | 149 | 2 |
| ANN-004 Drug Profile | 151 | 1 |
| AR-101 Drug Profile | 152 | 3 |
| AR-460770 Drug Profile | 155 | 1 |
| ARN-077 Drug Profile | 156 | 1 |
| ASP-0892 Drug Profile | 157 | 2 |
| ASP-4070 Drug Profile | 159 | 2 |
| AVA-1075 Drug Profile | 161 | 1 |
| BD-750 Drug Profile | 162 | 1 |
| Biologic for Cedar Pollen Allergy Drug Profile | 163 | 1 |
| Biosimilar for Allergy Drug Profile | 164 | 1 |
| Birch Pollen Allergoid Drug Profile | 165 | 1 |
| BM-31 Drug Profile | 166 | 1 |
| BM-32 Drug Profile | 167 | 3 |
| BM-34 Drug Profile | 170 | 1 |
| BM-35 Drug Profile | 171 | 1 |
| BM-36 Drug Profile | 172 | 1 |
| CG-201 Drug Profile | 173 | 1 |
| clustoid wiesenlieschgras Drug Profile | 174 | 1 |
| CWF-0808 Drug Profile | 175 | 1 |
| DBV-712 Drug Profile | 176 | 8 |
| DN-1105 Drug Profile | 184 | 1 |
| Drug for Egg Allergy Drug Profile | 185 | 1 |
| Drug for Egg Allergy Drug Profile | 186 | 1 |
| Drug for Food Allergy Drug Profile | 187 | 1 |
| Drug for Rheumatoid Arthritis and Allergies Drug Profile | 188 | 1 |
| Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma Drug Profile | 189 | 1 |
| E-0001163 Drug Profile | 190 | 1 |
| E-3.56 Drug Profile | 191 | 1 |
| E-34935 Drug Profile | 192 | 1 |
| E-35018 Drug Profile | 193 | 1 |
| epinephrine Drug Profile | 194 | 2 |
| epinephrine Drug Profile | 196 | 1 |
| epinephrine Drug Profile | 197 | 1 |
| Epsi-Gam Drug Profile | 198 | 2 |
| ET-523 Drug Profile | 200 | 1 |
| formoterol fumarate Drug Profile | 201 | 1 |
| HALMPE-1 Drug Profile | 202 | 1 |
| ICE-1203 Drug Profile | 203 | 1 |
| ICE-1204 Drug Profile | 204 | 1 |
| INT-301 Drug Profile | 205 | 1 |
| IPP-201007 Drug Profile | 206 | 1 |
| JCC-LAMP-Vax Drug Profile | 207 | 1 |
| JDP-207 Drug Profile | 208 | 1 |
| JTE-051 Drug Profile | 209 | 1 |
| JTE-451 Drug Profile | 210 | 1 |
| levocetirizine dihydrochloride Drug Profile | 211 | 1 |
| MB-11319 Drug Profile | 212 | 1 |
| Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders Drug Profile | 213 | 1 |
| Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders Drug Profile | 214 | 1 |
| montelukast sodium Drug Profile | 215 | 1 |
| Multi-LAMP-Vax Drug Profile | 216 | 1 |
| Next Generation Allergy Immunotherapy Drug Profile | 217 | 1 |
| oleyl alcohol Drug Profile | 218 | 1 |
| omalizumab biosimilar Drug Profile | 219 | 1 |
| Peanut Allergy Vaccine Drug Profile | 220 | 1 |
| PER-1080 Drug Profile | 221 | 1 |
| PL-101 Drug Profile | 222 | 1 |
| PL-102 Drug Profile | 223 | 1 |
| PL-103 Drug Profile | 224 | 1 |
| pnut-ASIT Drug Profile | 225 | 1 |
| Pollinex Quattro Grass Drug Profile | 226 | 3 |
| Polysaccharide for Oncology, Infectious Disease and Pollen Allergy Drug Profile | 229 | 1 |
| Polyvac Peanut Drug Profile | 230 | 1 |
| Proteins for Asthma and Allergy Drug Profile | 231 | 1 |
| Pru p 3 Allergen for Peach Allergy Drug Profile | 232 | 1 |
| Pru p 3 C1 Allergen for Peach Allergy Drug Profile | 233 | 1 |
| Recombinant Peptide to Inhibit Calcineurin for Rheumatoid Arthritis and Hypersensitivity Drug Profile | 234 | 1 |
| Recombinant Protein for Allergy Drug Profile | 235 | 1 |
| Recombinant Protein for Oncology, Allergies and Viral Infections Drug Profile | 236 | 1 |
| Recombinant Protein for Peanut Allergy Drug Profile | 237 | 1 |
| Recombinant Protein to Activate Gal-1 for Immunology Drug Profile | 238 | 1 |
| REGN-19081909 Drug Profile | 239 | 1 |
| RGI-1001 Drug Profile | 240 | 1 |
| SC-01 Drug Profile | 241 | 1 |
| SC-02 Drug Profile | 242 | 1 |
| SCV-204 Drug Profile | 243 | 1 |
| SCV-209 Drug Profile | 244 | 1 |
| SLP-0901 Drug Profile | 245 | 1 |
| Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders Drug Profile | 246 | 1 |
| Small Molecule to Inhibit IgE for Allergies Drug Profile | 247 | 1 |
| Small Molecule to Inhibit IL-6 for Autoimmune Disorders and Oncology Drug Profile | 248 | 1 |
| Small Molecules for Ocular Allergies Drug Profile | 249 | 1 |
| Soluble Beta Glucan Drug Profile | 250 | 3 |
| standardized grass pollen [timothy (Phleum pratense)] allergen extract Drug Profile | 253 | 3 |
| standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract Drug Profile | 256 | 2 |
| standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile | 258 | 5 |
| STG-160 Drug Profile | 263 | 1 |
| SWE-01 Drug Profile | 264 | 1 |
| SWE-04 Drug Profile | 265 | 1 |
| Synthetic Peptides for Allergy Drug Profile | 266 | 1 |
| tezepelumab Drug Profile | 267 | 2 |
| TN-LAMP-vax Drug Profile | 269 | 1 |
| TO-206 Drug Profile | 270 | 1 |
| TR-8 Drug Profile | 271 | 1 |
| tulobuterol Drug Profile | 272 | 1 |
| UB-221 Drug Profile | 273 | 1 |
| Vaccine for Allergy Drug Profile | 274 | 1 |
| Vaccine for Alternaria Allergy Drug Profile | 275 | 1 |
| Vaccine for Birch Pollen Allergy Drug Profile | 276 | 1 |
| Vaccine for Cat Allergy Drug Profile | 277 | 1 |
| Vaccine for Cedar Pollen Allergy Drug Profile | 278 | 1 |
| Vaccine for Food Allegy 2 Drug Profile | 279 | 1 |
| Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis Drug Profile | 280 | 2 |
| Vaccine for Japanese Cedar Pollen Allergy Drug Profile | 282 | 1 |
| Vaccine for Peanut Allergy Drug Profile | 283 | 1 |
| Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies Drug Profile | 284 | 1 |
| Vaccines for Peach Allergy Drug Profile | 285 | 1 |
| VTC-064 Drug Profile | 286 | 1 |
| Hypersensitivity Dormant Projects | 287 | 11 |
| Hypersensitivity Discontinued Products | 298 | 1 |
| Hypersensitivity Product Development Milestones | 299 | 13 |
| Featured News &Press Releases | 299 | 1 |
| Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy | 299 | 1 |
| Sep 20, 2016: Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. | 299 | 1 |
| Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B | 300 | 1 |
| Aug 18, 2016: Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children | 301 | 1 |
| Aug 01, 2016: DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy | 302 | 1 |
| Jul 06, 2016: AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial | 303 | 1 |
| Jul 05, 2016: DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer | 303 | 1 |
| Jun 27, 2016: DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children | 304 | 1 |
| Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204 | 304 | 1 |
| Jun 21, 2016: Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer | 305 | 1 |
| Jun 21, 2016: DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere | 306 | 1 |
| Jun 15, 2016: DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression | 307 | 1 |
| Jun 13, 2016: DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT Provides Sustained Protection Against Anaphylaxis | 308 | 1 |
| Jun 13, 2016: Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy | 309 | 1 |
| Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children | 310 | 2 |
| Appendix | 312 | 2 |
| Methodology | 312 | 1 |
| Coverage | 312 | 1 |
| Secondary Research | 312 | 1 |
| Primary Research | 312 | 1 |
| Expert Panel Validation | 312 | 1 |
| Contact Us | 312 | 1 |
| Disclaimer | 313 | 1 |